MindMaze Therapeutics Launches MindMotion Lite for Home-Based Neurorehabilitation

MindMaze Therapeutics, a global leader in scalable precision neurotherapeutics, is set to launch MindMotion Lite by the end of 2026. Designed for home-based use, this new solution aims to expand access to intensive neurorehabilitation for patients.

MindMotion Lite will bring the full range of MindMotion neurotherapeutic activities to a tablet-based format, significantly reducing the hardware requirements for home deployment. This new offering retains full-body rehabilitation capabilities, engaging patients in intensive training while offering a more accessible user experience tailored for home use. The tablet also supports teleconsultation and remote management, enabling healthcare professionals to continue supporting patients beyond the clinic.

"Our goal is to make intensive neurorehabilitation accessible to all and a routine part of patients' lives beyond the clinic. The AHA/ASA guidelines, updated in August 2026, emphasize the importance of sufficient rehabilitation intensity and continuity of care after stroke, yet access to continued neurotherapy after patients return home remains a critical gap. MindMotion Lite is designed to help close that gap."

The new solution complements MindMaze Therapeutics' existing platform, which combines therapeutic software, sensors, and specialized hardware for neurorehabilitation across the continuum of care. MindMotion Lite's tablet-based format is designed to enhance patient experience, streamline distribution, and reduce home deployment costs compared to MindMotion GO. This supports a more scalable and capital-efficient expansion of the company's home-based offering.

Ahead of launch, the company will preview MindMotion Lite at upcoming clinical, healthcare, and investor conferences. Further details on commercial availability and launch markets will be shared closer to the launch date.

MindMaze Therapeutics, a global leader in scalable, precision neurotherapeutics, is dedicated to redefining the recovery trajectory for patients around the world. By integrating advanced software, proprietary sensors, and AI-driven data analytics, the company provides a seamless continuum of care from the acute hospital phase to outpatient treatment to home-based therapy. The company's FDA-listed and CE-marked products are designed to address the systemic shortage of specialized clinicians, offering scalable, reimbursable solutions for stroke, Parkinson's disease, and other neurological disorders. With an extensive library of rigorous clinical validation, MindMaze Therapeutics is operationalizing the future of neurorestorative medicine.